House Bill 3379
116th Congress(2019-2020)
PRICED Act
Introduced
Introduced in House on Jun 20, 2019
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
3379
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
No House votes have been held for this bill.
Summary
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.
This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
June 20, 2019
06/21/2019
Referred to the Subcommittee on Health.
06/20/2019
Referred to the House Committee on Energy and Commerce.
06/20/2019
Introduced in House
Public Record
Record Updated
Nov 1, 2022 1:51:00 PM